Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYRA: Olaparib maintenance re-administration in platinum-sensitive recurrent ovarian cancer
jRCT1061230030Active, not recruiting
- Sponsor
- Okayama University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of olaparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Okayama University. Primary endpoint: Progression-free survival rate at 1 year. Started Aug 2023; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT1061230030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230030.